Bone Biologics Corp

Bone Biologics Corp. operates as a medical device company. engages in the research and development of bone regeneration in spinal fusion. Its product is Nell-1, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. Its platform technology has application in delivering improved outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. The company was founded by Eric Kang Ting, Chia Soo and Benjamin Wu in 2004 and is headquartered in Burlington, MA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced the closing of its previously announced public offering of an aggregate of 781,251 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 781,251 shares of common stock, at a public offering price of $2.56 per share (or common stock equivalent in l.

Bone Biologics Announces Closing of $2.0 Million Public Offering

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced the pricing of its public offering of an aggregate of 781,251 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 781,251 shares of common stock, at a public offering price of $2.56 per share (or common stock equivalent in lieu thereof) and acco.

Bone Biologics Announces Pricing of $2.0 Million Public Offering

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, reports progress with advancing its product candidate NB1 into human clinical testing for spinal fusion. Following Human Research Ethics Committee (HREC) approval last year in Australia for the multicenter, prospective, randomized pilot clinical trial, the Company reports that three hospital sites have been engaged to participate in the pilot clinical tr.

Bone Biologics Reports Progress With NB1 Clinical Program

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced that effective immediately Robert E. Gagnon has been named to the Company's board of directors. Mr. Gagnon fills the seat left by Erick Lucera, who has resigned effective upon Mr. Gagnon's appointment. The number of directors of Bone Biologics remains at four. Mr. Gagnon is currently chief financ.

Bone Biologics Appoints Healthcare Finance Veteran Robert E. Gagnon to Board of Directors

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced that it has received notice from The NASDAQ Stock Market LLC (Nasdaq) informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Bone Biologics is now in compliance with all.

Bone Biologics Regains Compliance with Nasdaq Continued Listing Requirements

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced a planned reverse stock split of its shares of common stock at a ratio of 1-for-8. The reverse stock split will take effect as of 12:01 a.m. ET, on Wednesday, December 20, 2023, and shares of Bone Biologics are expected to trade on a post-split basis on Nasdaq under the existing trading symbol, “.

Bone Biologics Announces 1-for-8 Reverse Stock Split

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of an aggregate of 1,139,063 of its shares of common stock at a purchase price of $0.64 per share. In a concurrent private placement, the Company also issued and sold unregistered warrants to purchase up to an aggregate of 1,139,063.

Bone Biologics Announces Closing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Bone Biologics (NASDAQ: BBLG ) stock is falling on Friday after the medical device company's shares underwent a major rally the day prior. That rally was caused by heavy trading of BBLG stock.

Why Is Bone Biologics (BBLG) Stock Down 38% Today?

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 1,139,063 of its shares of common stock at a purchase price of $0.64 per share in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the company has also agreed to issue and sell unregistered w.

Bone Biologics Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Bone Biologics (NASDAQ: BBLG ) stock is rocketing higher despite a lack of news from the medical device company on Thursday. There are no new press releases or filings with the Securities and Exchange Commission that explain why BBLG stock is up today.

Why Is Bone Biologics (BBLG) Stock Up 84% Today?

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, provides an update on its clinical development initiatives with its NB1 bone graft device. NB1 consists of the recombinant human protein NELL-1 combined with demineralized bone matrix (DBM). The 30-patient pilot study is expected to be conducted in Australia. Earlier this year, the Human Research Ethics Committee approved Monash Health as the first site.

Bone Biologics Provides Scientific Update on NB1 Bone Graft Device

Fresh2 Group Ltd

VistaGen Therapeutics

Yield10 Bioscience

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 4 Health Care Stocks Which Could Rescue Your Portfolio This Month - Bone Biologics (NASDAQ:BBLG), Fresh2 Group (NASDAQ:FRES)

Shares of Bone Biologics Corp. BBLG plummeted 51.9% toward a record low in premarket trading Thursday, after the developer of regenerative medicine for bones announced the pricing of its relatively large stock offering at a deep discount. The company raised $5 million, as it said overnight that it sold 2.54 million shares, which represented 15.2% of the shares outstanding, at price of $1.97 per share.

Bone Biologics stock plummets more than 50% after stock offering prices at deep discount

Bone Biologics (NASDAQ: BBLG ) stock is breaking down on Thursday after the company announced the details of a public share offering. Bone Biologics has revealed its public offering prices shares of BBLG stock at $1.97 each.

Why Is Bone Biologics (BBLG) Stock Down 52% Today?

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (NASDAQ: BBLG) (“Bone Biologics” or the “Company”), a developer of orthobiologic products for spine fusion markets, today announced the pricing of an underwritten public offering of common stock. Bone Biologics is selling 2,538,071 shares of its common stock in the offering. The shares of common stock are being sold at a price to the public of $1.97 per share, for aggregate gross proceeds of approximately $5.0 million, before deduct.

Bone Biologics Prices $5.0 Million Underwritten Public Offering

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, announces that a 1-for-30 reverse stock split became effective on June 5, 2023 and that its common stock and warrants will begin trading on a split-adjusted basis with the open of the market on June 7, 2023. Bone Biologics' common stock and warrants will continue to trade on Nasdaq under the symbols "BBLG" and “BBLGW”, respectively As a result of the rev.

Bone Biologics Effects 1-for-30 Reverse Stock Split

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, announces that the Human Research Ethics Committee (HREC) has approved Monash Health as the first of a planned multicenter pilot clinical trial to evaluate the Company's NB1 bone graft in Australia.

Bone Biologics Receives Human Research Ethics Committee Approval to Begin Pilot Clinical Trial with NB1 in Spinal Fusion Patients in Australia

BURLINGTON, Mass.--( BUSINESS WIRE )--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, announces it has engaged Avania as the contract research organization (CRO) for the Company's pilot clinical trial with NB1. Avania is an integrated global, full-service CRO with specialized expertise in medical devices, novel technology and drug-device combination products. The trial will evaluate the safety and effectiveness of Bone Biologic's novel NB1 in patients with degenerative disc disease undergoing a Transforaminal Lumbar Interbody Fusion (TLIF) procedure.

Bone Biologics Advances Preparations for NB1 Pilot Clinical Trial with Engagement of Contract Research Organization

Akebia Therapeutics

Hillstream Biopharma

HTG Molecular Diagnostics

Kalera PLC

Pagaya Technologies Ltd

SINTX Technologies Inc

Sio Gene Therapies

Venator Materials

Wearable Devices Ltd

Penny stocks to watch trading under $1 right now. The post Penny Stocks To Buy Now?

Penny Stocks To Buy Now? 10 Stocks Under $1 To Watch

Bone Biologics CEO Issues Letter to Stockholders

JERSEY CITY, N.J. , Oct. 13, 2022 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services announced yesterday the closing of Bone Biologics (NASDAQ: BBLG) previously announced underwritten public offering of units of securities for total gross proceeds of $5,100,000, before deducting underwriting discounts and commissions and other estimated offering expenses.

WallachBeth Capital Announces Closing of Bone Biologics $5,100,000 Underwritten Public Offering

Bone Biologics Announces Closing of $5,100,000 Underwritten Public Offering

The stock price of Bone Biologics (BBLG) dropped by 35.53% in the most recent trading session. This is why.

Bone Biologics (BBLG) Stock: Why It Dropped 35.53%

BURLINGTON, Mass.--(BUSINESS WIRE)--Reissuing release to remove "million" after "$5,100,000" in the headline and first sentence of the text. The updated release reads: BONE BIOLOGICS PRICES $5,100,000 UNDERWRITTEN PUBLIC OFFERING Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, announces the pricing of an underwritten public offering of 3,777,778 units of securities at an offering price of $1.35 per unit, for total gross proceeds of $5,1

CORRECTING and REPLACING Bone Biologics Prices $5,100,000 Underwritten Public Offering

JERSEY CITY, N.J. , Oct. 7, 2022 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion, announced the pricing of an underwritten public offering of 3,777,778 units at an offering price of $1.35 per unit, for total gross proceeds of $5,100,000 before deducting underwriting discounts and commissions and other offering expenses.

News for Bone Biologics Corp Stock (BBLG)